Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
RF ablation for varicose veins: VNUS Medical Technologies' ClosureFAST radiofrequency ablation system for treatment of venous reflux, the underlying cause of symptomatic varicose veins, is "significantly superior" to endovenous laser treatment as measured by quality-of-life and post-procedural recovery parameters, according to results of the 69-patient RECOVERY multicenter, randomized study by Jose Almeida, Miami Vein Center, et al, published in the June issue of the Journal of Vascular & Interventional Radiology. The patients treated with ClosureFAST had less postoperative pain and bruising and better reduction of symptoms than the laser-treated patients as early as two days post-procedure and continued to show better outcomes two weeks after the treatment; however, equalization in most parameters was observed between the two groups by one month. All quality-of-life parameters were significantly better, and minor complications were five times less common, in the ClosureFAST group. Covidien recently signed a deal to acquire VNUS for $440 million (1"The Gray Sheet" May 11, 2009, p. 15)
You may also be interested in...
Cook Medical Makes Progress In Peripheral Stent Space
Cook Medical is making advances in the peripheral stent market with the imminent launch of its Formula balloon-expandable renal stent system, and a recent report of two-year data for its PMA-pending Zilver PTX paclitaxel-eluting stent.
Cook Medical Makes Progress In Peripheral Stent Space
Cook Medical is making advances in the peripheral stent market with the imminent launch of its Formula balloon-expandable renal stent system, and a recent report of two-year data for its PMA-pending Zilver PTX paclitaxel-eluting stent.
Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy
Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million